New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.
about
New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progressionPrevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohortThe Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerProteomics in prostate cancer biomarker discovery.PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer.PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.Circulating Long Noncoding RNA as a Potential Target for Prostate CancerFuture opportunities for the diagnosis and treatment of prostate cancer.Gene therapy in urology: strategies to translate theory into practice.Regulators of gene expression as biomarkers for prostate cancerEvaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.New therapeutic targets in the treatment of prostate cancer.RNAi and cancer: Implications and applications.PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis.How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer.A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.Microarray analysis of copy-number variations and gene expression profiles in prostate cancer.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients.FARNA: knowledgebase of inferred functions of non-coding RNA transcripts.No-match ORESTES explored as tumor markers.Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells.Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stageCarcinogenesis in prostate cancer: The role of long non-coding RNAs
P2860
Q21143810-74BB0939-5F5B-4769-BD9B-4D7DEDF91D34Q24606772-5E347DFD-5598-4765-A192-76EBE985D68EQ26738703-EEF7ADDC-C258-47B4-9627-6733372775EAQ34096086-46CF3831-C37F-4A8E-87D0-1822A9B20B19Q34457066-8DD9F34E-7F19-4287-92EE-7E9EA8C8D6C8Q34468270-44F2A74A-DC11-44BB-BA6C-2904050B5D3FQ34536729-C0EC9FFC-8B74-47B6-99A6-942A65513BEBQ34984413-105FE56C-3CCC-4101-A0B7-26096A78B48FQ35814012-0358A3F0-0F0F-40C6-85E1-9E20DB372B7EQ35886572-77ED8DC9-8411-4043-B14A-F46CFB2B49BBQ36312228-6896E764-E18F-4B10-AB54-286F947404EBQ36439912-B307E288-4EEE-4110-BCE6-F7AFD0BA75A6Q36886346-47CC298A-1708-47FF-BA54-9B5D123A6173Q37290963-AEA56635-96FC-4688-921E-F1D6230A53A6Q37331654-D68AA626-EC21-487D-9668-438628E57B9BQ38166577-04DF84F9-7CCB-4902-8082-5A56B6E97EA1Q38191938-10E5DCF6-CC98-4A73-8239-104F9CB7131EQ38602540-56D42194-AE1F-402B-AB7A-0B544FD6E9E6Q38682456-F12DA0FB-B379-4585-82EF-E94EC306C1F5Q38786630-51C3F126-31DD-431F-9928-CD8B1EE3548FQ38817672-B97CD2B7-D74D-49E7-BC00-3DF5A7993BD0Q40072464-FA9BFD7F-C785-4227-BC27-DC8BD4FF59A4Q40104911-3025DA21-DD16-4B24-AED5-EC1BAA26F285Q40167317-3532628A-EF4C-47B7-9E8F-D83D6267965EQ40335045-0C35A390-F4F7-49B7-98EB-DEFE0389A797Q41821320-82CF53AB-ACA2-4FE6-9A5F-915BF2EF045FQ42614334-4FC5EE7B-C474-4DA6-B66D-E59935E95C84Q48252578-99268B18-F5E7-46B9-B9A9-717AB20521DAQ51391966-EAECCC3D-0830-445E-9AEB-6DEB7A0789D4Q56741962-C1DD36F5-89B5-45D5-B263-EFAE813FB886Q57114753-52B8C17A-8A60-467E-AEC9-735E01473FBA
P2860
New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
New targets for therapy in pro ...... prostate cancer-specific gene.
@ast
New targets for therapy in pro ...... prostate cancer-specific gene.
@en
New targets for therapy in pro ...... prostate cancer-specific gene.
@nl
type
label
New targets for therapy in pro ...... prostate cancer-specific gene.
@ast
New targets for therapy in pro ...... prostate cancer-specific gene.
@en
New targets for therapy in pro ...... prostate cancer-specific gene.
@nl
prefLabel
New targets for therapy in pro ...... prostate cancer-specific gene.
@ast
New targets for therapy in pro ...... prostate cancer-specific gene.
@en
New targets for therapy in pro ...... prostate cancer-specific gene.
@nl
P2093
P1433
P1476
New targets for therapy in pro ...... prostate cancer-specific gene.
@en
P2093
Daphne Hessels
Gerald Verhaegh
Jack A Schalken
P356
10.1016/S0090-4295(03)00759-3
P407
P433
P577
2003-11-01T00:00:00Z